Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
121
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Imogen Caldwella Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, AustraliaCorrespondence[email protected]
,
David Byrnea Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Stephen Ladea Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Tim Akhurstb Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Adrian Minsonc Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
,
Michael Dickinsonc Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
,
Ella Thompsona Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
,
Clare Scottd Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia;e The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;f Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
&
Piers Blomberya Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
 show all
Pages 3521-3525 | Received 16 May 2021, Accepted 31 Jul 2021, Published online: 14 Aug 2021

References

  • Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. revised 4th ed. Lyon: IARC; 2017.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
  • Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–3156.
  • Ryland GL, Jones K, Chin M, et al. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. J Clin Pathol. 2018;71(10):895–899.
  • Blombery PA, Ryland GL, Markham J, et al. Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay. Br J Haematol. 2018;183(1):146–149.
  • McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228(1):20–30.
  • Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341–347.
  • Barnes JA, Jacobsen E, Feng Y, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98(4):615–619.
  • Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol. 2006;134(5):475–484.
  • Weeber F, Cirkel GA, Hoogstraat M, et al. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. Oncotarget. 2017;8(33):55582–55592.
  • Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(30):12420–12425.
  • Erdmann T, Klener P, Lynch JT, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130(3):310–322.
  • Bhatti M, Ippolito T, Mavis C, et al. Pre-clinical activity of targeting the PI3K/akt/mTOR pathway in burkitt lymphoma. Oncotarget. 2018;9(31):21820–21830.
  • Li J, Liu X, Yao Z, et al. High-grade B-cell lymphomas, not otherwise specified: a study of 41 cases. Cancer Manag Res. 2020;12:1903–1912.
  • Winter AM, Landsburg DJ, Mato AR, et al. A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. Blood. 2017;130(14):1676–1679.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.